Becton, Dickinson and Company (NYSE:BDX) Releases FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 14.300-14.600 for the period, compared to the consensus earnings per share estimate of 14.350. The company issued revenue guidance of $21.7 billion-$21.9 billion, compared to the consensus revenue estimate of $21.9 billion.

Becton, Dickinson and Company Stock Up 1.1 %

Becton, Dickinson and Company stock traded up $2.65 during mid-day trading on Wednesday, reaching $245.07. 2,061,265 shares of the company’s stock were exchanged, compared to its average volume of 2,046,401. The company has a fifty day moving average of $231.33 and a 200-day moving average of $234.02. The company has a market cap of $71.07 billion, a P/E ratio of 41.26, a P/E/G ratio of 1.80 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Sell-side analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.70%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company declared that its board has authorized a share buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have commented on BDX. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $283.00.

Insiders Place Their Bets

In related news, EVP David Shan sold 500 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. This represents a 8.01 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,844 shares of company stock valued at $2,210,716 over the last 90 days. 0.36% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.